JP2838073B2 - 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物 - Google Patents

痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物

Info

Publication number
JP2838073B2
JP2838073B2 JP8188120A JP18812096A JP2838073B2 JP 2838073 B2 JP2838073 B2 JP 2838073B2 JP 8188120 A JP8188120 A JP 8188120A JP 18812096 A JP18812096 A JP 18812096A JP 2838073 B2 JP2838073 B2 JP 2838073B2
Authority
JP
Japan
Prior art keywords
snx
conopeptide
mviia
active
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP8188120A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09104634A (ja
Inventor
アーサー アムステュッツ ガリー
スコット バワースオックス スティーブン
ゴヒル キッショーチャンドラ
アイサドール アドルエンセンス ピーター
クリスティパティ ラマシャーマ
ガッドボイス テレサ
レイモンド ペテス マーク
アール． ルーサー ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYUURETSUKUSU CORP
Original Assignee
NYUURETSUKUSU CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by NYUURETSUKUSU CORP filed Critical NYUURETSUKUSU CORP
Publication of JPH09104634A publication Critical patent/JPH09104634A/ja
Application granted granted Critical
Publication of JP2838073B2 publication Critical patent/JP2838073B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP8188120A 1995-06-27 1996-06-27 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物 Expired - Fee Related JP2838073B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/496,847 1995-06-27
US08/613,400 1996-03-08
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (2)

Publication Number Publication Date
JPH09104634A JPH09104634A (ja) 1997-04-22
JP2838073B2 true JP2838073B2 (ja) 1998-12-16

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8188120A Expired - Fee Related JP2838073B2 (ja) 1995-06-27 1996-06-27 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物

Country Status (13)

Country Link
EP (2) EP1336409B1 (2)
JP (1) JP2838073B2 (2)
AT (2) ATE359086T1 (2)
AU (1) AU695166B2 (2)
CA (1) CA2224795C (2)
DE (3) DE69627153T2 (2)
DK (2) DK0835126T3 (2)
ES (2) ES2283671T3 (2)
FR (1) FR05C0027I2 (2)
LU (1) LU91181I2 (2)
NL (1) NL300201I2 (2)
PT (2) PT1336409E (2)
WO (1) WO1997001351A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP2002509080A (ja) * 1998-02-20 2002-03-26 シンジェンタ リミテッド グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US8673856B2 (en) * 2006-11-04 2014-03-18 Anygen Co., Ltd. Omega conotoxins
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009135258A1 (en) * 2008-05-06 2009-11-12 Cnsbio Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
DE122005000043I2 (de) 2006-08-03
DK0835126T3 (da) 2003-07-14
JPH09104634A (ja) 1997-04-22
ES2194998T3 (es) 2003-12-01
AU6400296A (en) 1997-01-30
EP1336409B1 (en) 2007-04-11
LU91181I2 (fr) 2005-09-06
ATE235914T1 (de) 2003-04-15
ATE359086T1 (de) 2007-05-15
NL300201I1 (nl) 2005-09-01
EP1336409A1 (en) 2003-08-20
DE122005000043I1 (de) 2006-06-29
EP0835126A1 (en) 1998-04-15
DE69637021D1 (de) 2007-05-24
DE69637021T2 (de) 2008-01-10
PT835126E (pt) 2003-07-31
AU695166B2 (en) 1998-08-06
DE69627153T2 (de) 2003-12-04
FR05C0027I1 (2) 2005-08-12
FR05C0027I2 (2) 2006-12-29
WO1997001351A1 (en) 1997-01-16
HK1058146A1 (en) 2004-05-07
DK1336409T3 (da) 2007-08-13
PT1336409E (pt) 2007-06-29
CA2224795A1 (en) 1997-01-16
CA2224795C (en) 2001-04-03
ES2283671T3 (es) 2007-11-01
NL300201I2 (nl) 2006-02-01
EP0835126B1 (en) 2003-04-02
DE69627153D1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
JP2838073B2 (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
US5795864A (en) Stable omega conopetide formulations
US6054429A (en) Epidural method of producing analgesia
EP0625162B1 (en) Methods of producing analgesia and enhancing opiate analgesia
Taylor Agents acting at the neuromuscular junction and autonomic ganglia
AU648052B2 (en) Compositions for treating ischemia-related neuronal damage
AU2009288088B2 (en) Agents and methods for treatment of pain
CN101678068B (zh) 不抑制n型钙通道而治疗中风和其他疾病
JP6279626B2 (ja) エンドモルフィンのμオピオイド受容体アゴニスト類似体
US6136786A (en) Method for enhancing analgesia
US20040138204A1 (en) Compositions and methods for pain reduction
WO2018068670A1 (zh) 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
JPH10511077A (ja) Ｎ末端基で切断されたダイノルフィン類似体を用いた鎮痛方法
JP6000245B2 (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
WO1993010145A1 (en) Compositions for delayed treatment of ischemia-related neuronal damage
HK1058146B (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
JP2002509080A (ja) グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
HK1013832B (en) Methods of producing analgesia and enhancing opiate analgesia

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 19980910

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071009

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081009

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091009

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091009

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101009

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 13

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 13

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111009

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131009

Year of fee payment: 15

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees